Answers are grounded in this paper and cite their sources.
Real-world study shows immune-based combinations improve outcomes in elderly patients, indicating potential benefits despite lower survival rates.
This large real-world study with mRCC patients substantiates the effectiveness and safety of first-line immune-based combination treatments in elderly patients. Nonetheless, this population has a lower survival in comparison to younger patients.
No takes yet. Share an insight, caveat, or question.
MARUZZO et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: